Does ENZALUTAMIDE Cause Therapy non-responder? 29 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 29 reports of Therapy non-responder have been filed in association with ENZALUTAMIDE (Xtandi). This represents 0.1% of all adverse event reports for ENZALUTAMIDE.
29
Reports of Therapy non-responder with ENZALUTAMIDE
0.1%
of all ENZALUTAMIDE reports
2
Deaths
3
Hospitalizations
How Dangerous Is Therapy non-responder From ENZALUTAMIDE?
Of the 29 reports, 2 (6.9%) resulted in death, 3 (10.3%) required hospitalization, and 1 (3.4%) were considered life-threatening.
Is Therapy non-responder Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENZALUTAMIDE. However, 29 reports have been filed with the FAERS database.
What Other Side Effects Does ENZALUTAMIDE Cause?
Fatigue (8,891)
Death (6,680)
Malignant neoplasm progression (4,696)
Prostatic specific antigen increased (3,731)
Asthenia (3,589)
Drug ineffective (3,468)
Hot flush (3,144)
Decreased appetite (3,069)
Nausea (2,898)
Dizziness (2,776)
What Other Drugs Cause Therapy non-responder?
ETANERCEPT (3,472)
APREMILAST (3,360)
METHOTREXATE (2,965)
RITUXIMAB (2,731)
ADALIMUMAB (2,595)
PREDNISONE (2,563)
TREPROSTINIL (2,289)
INFLIXIMAB (2,122)
TOCILIZUMAB (1,775)
HYDROXYCHLOROQUINE (1,699)
Which ENZALUTAMIDE Alternatives Have Lower Therapy non-responder Risk?
ENZALUTAMIDE vs EPCORITAMAB
ENZALUTAMIDE vs EPCORITAMAB-BYSP
ENZALUTAMIDE vs EPERISONE
ENZALUTAMIDE vs EPHEDRINE
ENZALUTAMIDE vs EPINASTINE